55 related articles for article (PubMed ID: 38619081)
1. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis.
Zhang J; Cheng K; Wang Z
Arch Gynecol Obstet; 2020 Dec; 302(6):1329-1337. PubMed ID: 32914222
[TBL] [Abstract][Full Text] [Related]
2. Pattern of multiple human papillomavirus infection and type competition: An analysis in healthy Chinese women aged 18-45 years.
Su Y; Zheng T; Bi Z; Jia X; Li Y; Kuang X; Yang Y; Chen Q; Lin H; Huang Y; Huang S; Qiao Y; Wu T; Zhang J; Xia N
Hum Vaccin Immunother; 2024 Dec; 20(1):2334474. PubMed ID: 38619081
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
[TBL] [Abstract][Full Text] [Related]
4. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
6. Epidemiology and genotypes analysis of human papillomavirus infection in Beijing, China.
Wang J; Li H; Zhang J; Wang H; Li Y; Liu Z; Liu H
Virol J; 2024 Jan; 21(1):19. PubMed ID: 38229145
[TBL] [Abstract][Full Text] [Related]
7. Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.
Mesher D; Soldan K; Lehtinen M; Beddows S; Brisson M; Brotherton JM; Chow EP; Cummings T; Drolet M; Fairley CK; Garland SM; Kahn JA; Kavanagh K; Markowitz L; Pollock KG; Söderlund-Strand A; Sonnenberg P; Tabrizi SN; Tanton C; Unger E; Thomas SL
Emerg Infect Dis; 2016 Oct; 22(10):1732-40. PubMed ID: 27648688
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of genotyping of human papillomavirus by GP5+/6+-PCR-based reverse dot blot hybridization assay and SPF10-PCR-based line probe assay.
Yin J; Peng S; Li X; Zhang C; Hu F; Chen W; Qiao Y
J Med Virol; 2023 Feb; 95(2):e28435. PubMed ID: 36571268
[TBL] [Abstract][Full Text] [Related]
9. HPV type-specific trends in cervical precancers in the United States, 2008 to 2016.
Gargano JW; McClung N; Lewis RM; Park IU; Whitney E; Castilho JL; Pemmaraju M; Niccolai LM; Brackney M; DeBess E; Ehlers S; Bennett NM; Scahill M; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Int J Cancer; 2023 Jan; 152(2):137-150. PubMed ID: 35904861
[TBL] [Abstract][Full Text] [Related]
10. Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
Man I; Vänskä S; Lehtinen M; Bogaards JA
J Infect Dis; 2021 Aug; 224(3):481-491. PubMed ID: 31985011
[TBL] [Abstract][Full Text] [Related]
11. Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.
Wei LH; Su YY; Hu YM; Li RC; Chen W; Pan QJ; Zhang X; Zhao FH; Zhao YQ; Li Q; Hong Y; Zhao C; Li MQ; Liu WY; Li CH; Guo DP; Ke LD; Lin BZ; Lin ZJ; Chen S; Sheng W; Zheng ZZ; Zhuang SJ; Zhu FC; Pan HR; Li YM; Huang SJ; Zhang J; Qiao YL; Wu T; Xia NS
Clin Microbiol Infect; 2020 Aug; 26(8):1069-1075. PubMed ID: 31904566
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.
Qiao YL; Wu T; Li RC; Hu YM; Wei LH; Li CG; Chen W; Huang SJ; Zhao FH; Li MQ; Pan QJ; Zhang X; Li Q; Hong Y; Zhao C; Zhang WH; Li YP; Chu K; Li M; Jiang YF; Li J; Zhao H; Lin ZJ; Cui XL; Liu WY; Li CH; Guo DP; Ke LD; Wu X; Tang J; Gao GQ; Li BY; Zhao B; Zheng FX; Dai CH; Guo M; Zhao J; Su YY; Wang JZ; Zhu FC; Li SW; Pan HR; Li YM; Zhang J; Xia NS
J Natl Cancer Inst; 2020 Feb; 112(2):145-153. PubMed ID: 31086947
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
14. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
